What is Sales and Marketing Strategy of Guerbet Company?

Guerbet's direct sales teams are fundamental to its Guerbet sales strategy, fostering direct relationships with hospitals, clinics, and imaging centers. This allows for tailored engagement and a deep understanding of customer needs.

A comprehensive network of wholesale distributors and partner retailers extends Guerbet's market reach. This network is crucial for efficient product delivery and market penetration across diverse geographical areas.

The company operates a worldwide distribution infrastructure, with significant regional platforms in Europe, Asia, North America, and South America. This ensures consistent and quality-controlled delivery of its pharmaceutical products.

Recent strategic adjustments have impacted sales channels. For example, a supply chain reform in France led to an 11.8% revenue decline in EMEA (excluding France) in 2024, with a continued fall in H1 2025. Conversely, the Americas region saw sales grow by 20.5% in 2024 at constant exchange rates, demonstrating strong market penetration.

With nearly a century of experience, Guerbet is a leader in contrast agents, enhancing image quality for better patient outcomes. The company's core message emphasizes improving diagnosis, monitoring, and treatment of various pathologies.

Guerbet differentiates itself through continuous innovation, particularly in developing advanced and safer contrast media. Elucirem™ (Gadopiclenol) exemplifies this, offering effective contrast enhancement at a reduced dose, appealing to safety-conscious healthcare providers.

Brand consistency is maintained across all global operations, from research and development to distribution. This ensures a unified reputation for high quality and reliability in the medical imaging market.

The company's financial performance, with 2024 revenue reaching €841.1 million, and strategic investments in R&D exceeding 9% of sales, underscore its position as a trusted and forward-thinking entity.

A significant recent campaign centers on the global rollout of Elucirem™ (Gadopiclenol). Following its European market authorization in October 2023, Guerbet has actively pursued market penetration in the US and Europe throughout 2024 and 2025. The strategy focuses on establishing Elucirem™ as a premier MRI contrast agent by highlighting its high relaxivity and efficacy at a reduced gadolinium dose.

The sustained success of Lipiodol® in Interventional Imaging remains a cornerstone of Guerbet's strategy. In fiscal year 2024, this segment achieved €100 million in sales, with Lipiodol® being a principal contributor, especially in vascular embolization. This consistent growth, fueled by favorable pricing and robust volumes, demonstrates a highly effective long-term marketing approach for this established product.

Guerbet is actively campaigning its digital and AI solutions under the DUOnco™ brand, launched in April 2024. This initiative introduced Guerbet's inaugural AI algorithm for prostate cancer, integrated into the Myrian®12 platform. The subsequent CE certifications for DUOnco™ Liver and DUOnco™ Bone in late 2024 and early 2025, alongside the FDA's 'Breakthrough Device' designation for its pancreatic solution, underscore a strategic push to lead in AI-enhanced diagnostics.

These AI-focused campaigns aim to build visibility and credibility within the rapidly evolving digital health sector. Guerbet is leveraging strategic partnerships, such as the collaboration with Intrasense for platform integration, to enhance its market presence and showcase its innovative digital capabilities.